Skip to main content

Table 2 Predicted effectiveness of the screening programme per 100,000 neonates

From: Newborn screening by tandem mass spectrometry for glutaric aciduria type 1: a cost-effectiveness analysis

20 years horizon Mean value 95% CI
Life years gained 1.0 0.7 – 1.4
DALY averted 3.7 2.9 – 4.5
70 years horizon Mean value 95% CI
Life years gained 4.1 3.0 – 5.7
DALY averted 6.0 4.7 – 7.5